Clinical trials: Essential Hypertension.
Hypertension
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
The primary objective was to determine the effects of the Gastrointestinal Therapeutic System (GITS) formulation of Doxazosin when used in combination therapy with the 5 major classes of antihypertensive agents as measure by…
- Trial name
- NCT00646841
- Testing
- Doxazosin gastrointestinal therapeutic system (GITS)
- Where
- 7 sites in Italy, Spain and 1 more
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Essential Hypertension, White Coat Hypertension
Heart Rate Variability in White Coat Hypertension and Essential Hypertension
The aim of the study is to investigate heart rate variability in patients with white coat hypertension and patients with essential hypertension.
- Conditions
- Essential Hypertension, White Coat Hypertension, Healthy
- Trial name
- NCT00286884
- Testing
- Monitoring of heart rate variability
- Where
- Denmark
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
Hypertension,Essential, Exercise Activity
Effect of High-Intensity Interval Training Compared to Hydrochlorothiazide on Ambulatory Blood Pressure
The number of persons with hypertension is increasing and with it the number of related cardiovascular events and related functional or cognitive declines.
- Trial name
- DIISCCO (NCT04103411)
- Testing
- 24h-Ambulatory Blood Pressure
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anil Nigam
Pulmonary Hypertension, Primary, 4
Serum Bio-markers in Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by scarred blood clots in the blood vessels supplying the lungs. This in turn leads to failure of the right side of the heart.
- Trial name
- NCT04472533
- Where
- United Kingdom
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- Papworth Hospital NHS Foundation Trust
Hypertension
Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
In order to confirm the proposed metabolic effect of lacidipine these follow-up study was to provide long-term data on its impact on liver function, glucose homoeostasis and lipid metabolism.
- Trial name
- NCT02177331
- Testing
- Lacidipine
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Arterial Hypertension
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02521246
- Testing
- Candesartan + Chlorthalidone, Losartan+hydrochlorothiazide
- Sponsor
- EMS
Hypertension
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension
To assess the trough/peak ratio of 40 mg Telmisartan tablet by ambulatory blood pressure monitoring in Chinese patients with mild to moderate essential hypertension
- Trial name
- NCT02206659
- Testing
- Telmisartan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Primary Hypertension, Secondary Hypertension
Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
This open label 4 month study will evaluate efficacy (blood pressure lowering effects) and safety of lisinopril in children 1-18y whose parents grant permission to participate.
- Trial name
- Lisi-ped (NCT02184858)
- Testing
- lisinopril, ACE-inhibitor
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University Ghent
Hypertension, Metabolic Syndrome
Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study
Jangzhuo Qinggan prescription and irbesartan in the treatment of essential hypertension(Hepatogastric Damp-heat), randomized, parallel-controlled, multi-center clinical study.
- Trial name
- JZQG (NCT01082835)
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Hypertension,Essential
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
This study was to evaluate the therapeutic effect and safety of Amosartan Plus tablet administration in uncontrolled essential hypertension patients.
- Trial name
- NCT05462535
- Testing
- Amosartan Plus Tab.
- Where
- South Korea
- Volunteers
- 4,785 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is administered by subcutaneous injection.
- Trial name
- NCT00701649
- Testing
- CYT006-AngQb
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 60 people
- Sponsor
- Cytos Biotechnology AG
Essential Hypertension
Study MIPAE - Melatonin and Essential Arterial Hypertension
Study MIPAE - Melatonin and essential arterial hypertension. Study with dietary supplement, prospective and monocentric (randomized control trial).
- Trial name
- MIPAE (NCT05257291)
- Testing
- Melatonin
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
High Blood Pressure (Hypertension).
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
The purpose of this research study is to determine if treatment with the combination of metoprolol succinate and hydrochlorothiazide is more effective at lowering blood pressure than treatment with either of the two drugs alone.
- Trial name
- NCT00642096
- Testing
- Metoprolol Succinate, Hydrochlorothiazide
- Volunteers
- 1,900 people
- Sponsor
- AstraZeneca
Arterial Calcification, Aortic Stiffness
Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation
Central blood pressure and pulse wave velocity were measured using a Complior Analyse device in Short and Long-term after kidney transplantation.
- Conditions
- Arterial Calcification, Aortic Stiffness, High Blood Pressure (& [Essential Hypertension])
- Trial name
- PWV/CP/KTx (NCT02443454)
- Testing
- Device: Complior Analyse System, Tanita BC 418- Bioelectrical impedance analysis
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Essential Hypertension
Clinical Trial on Remote Ischemic Conditioning and Hypertension（HOPE）
Nowadays, the incidence of stroke in China has reached 1.6‰, and this disease has became a primary cause of death in China. One of its major risk factors is hypertension.
- Trial name
- NCT03566654
- Testing
- remote ischemic conditioning, ambulatory blood pressure monitoring
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Ji Xunming,MD,PhD
Hypertension (HTN), NYHA Class III Heart Failure
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to…
- Conditions
- Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure, Diabete Mellitus
- Trial name
- NCT07064525
- Testing
- SPC1001 Low, SPC5002, SPC5003
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Healthy Volunteers Essential Hypertension
Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension.
- Trial name
- NCT06823947
- Testing
- KK3910
- Where
- 3 sites in Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypertension, Myocardial Ischemia
Perioperative Myocardial Ischemia in Isolated Systolic Hypertension
During or after surgery, patients may suffer heart attacks or other heart complications, increasing the hospital stay by 11 days on average and costing an estimated US$20 billion in 1990.Many risk factors have been identified but…
- Trial name
- PROMISE (NCT01237652)
- Where
- Canada
- Volunteers
- 312 people
- Sponsor
- Ottawa Hospital Research Institute